Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica MorraDepartment of Oncology/Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca’ Granda Hospital, Milan, ItalyAbstract: The introduction of immunotherapeutic agents has provided ren...
Guardado en:
Autores principales: | Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica Morra |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8fca0c3e95b34ce59ae258549396da98 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
por: M. N Khorobrykh, et al.
Publicado: (2014) -
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
por: Irene Amigo-Jiménez, et al.
Publicado: (2014) -
Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci AM, et al.
Publicado: (2015) -
Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)
por: Kübra Kaban, et al.
Publicado: (2021) -
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
por: Federica Frezzato, et al.
Publicado: (2012)